ENDO - Sorrento Therapeutics: Insider Buying Alert
What do dogs do on their day off?; Can't lie around — that's their job!” ― George Carlin
Sorrento Therapeutics (SRNE) provided its shareholders with a roller coaster week. The stock initially soared as the company's ZTlido patch was approved by the FDA for treating patients with post-herpetic neuralgia pain.
As is want for these approvals, the initial rally in the stock eventually turned into a huge bout of profit taking to end the week. This is exactly why I sold covered calls on my position in Sorrento on the big rise